Early Detection Research Network

CDCP1

Aliases:
This biomarker is also known as:
  • CD318,
  • subtractive immunization M plus HEp3-associated 135 kDa protein,
  • CD318 antigen,
  • transmembrane and associated with src kinases,
  • Membrane glycoprotein gp140,
  • Q9H5V8,
  • Subtractive immunization M plus HEp3-associated 135 kDa protein,
  • TRASK,
  • membrane glycoprotein gp140,
  • CUB domain-containing protein 1,
  • CDCP1,
  • CUB domain containing protein 1,
  • SIMA135,
  • Transmembrane and associated with src kinases,

Description…

CDCP1 is a transmembrane protein containing three extracellular CUB domains. It is found to be overexpressed in colon and lung cancers. Its expression level is correlated with the metastatic ability of carcinoma cells. CDCP1 is located on the cell surface and may be involved in cell adhesion and cell matrix association. Alternatively spliced transcript variants encoding distinct isoforms have been reported.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: CDCP1

The following organs have data associated with this biomarker…

Attributes

Phase: Two
QA State: Under Review

Overview

CDCP1 is a transmembrane tumor vascular marker (TVM) that is selectively expressed in tumor vasculature and represents a promising target for vascular imaging or anti-vascular therapy of epithelial ovarian cancer.

Performance Comment

CDCP1 was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of CDCP1 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.